[go: up one dir, main page]

Fogler et al., 1986 - Google Patents

The activation of tumoricidal properties in human blood monocytes by muramyl dipeptide requires specific intracellular interaction.

Fogler et al., 1986

Document ID
18408967264003391065
Author
Fogler W
Fidler I
Publication year
Publication venue
Journal of immunology (Baltimore, Md.: 1950)

External Links

Snippet

The purpose of this study was to identify the mechanism by which muramyl dipeptide (MDP) activates antitumor cytotoxic properties in normal and interferon-gamma (IFN-gamma)- primed human peripheral blood monocytes. The structurally and functionally active MDP …
Continue reading at journals.aai.org (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Similar Documents

Publication Publication Date Title
Fogler et al. The activation of tumoricidal properties in human blood monocytes by muramyl dipeptide requires specific intracellular interaction.
Fidler et al. Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human interferon-gamma encapsulated in liposomes.
Saiki et al. Synergistic activation by recombinant mouse interferon-gamma and muramyl dipeptide of tumoricidal properties in mouse macrophages.
US4774085A (en) Pharmaceutical administration systems containing a mixture of immunomodulators
Kleinerman et al. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide
Kleinerman et al. Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines.
Sone et al. Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages.
Schroit et al. Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide
Poste et al. Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes
Sone et al. In vitro activation of tumoricidal properties in rat alveolar macrophages by synthetic muramyl dipeptide encapsulated in liposomes
Utsugi et al. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes
Phillips et al. Activation of alveolar macrophage tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative
Fidler et al. Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self
Koff et al. Human monocytes activated by immunomodulators in liposomes lyse herpesvirus-infected but not normal cells
Saiki et al. Synergism between human recombinant γ-interferon and muramyl dipeptide encapsulated in liposomes for activation of antitumor properties in human blood monocytes
Sone et al. Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes.
Fidler et al. Efficacy of liposomes containing a lipophilic muramyl dipeptide derivative for activating the tumoricidal properties of alveolar macrophages in vivo
Fidler et al. Synergism between lymphokines and muramyl dipeptide encapsulated in liposomes: in situ activation of macrophages and therapy of spontaneous cancer metastases.
Sone et al. Rat alveolar macrophages are susceptible to activation by free and liposome-encapsulated lymphokines.
Sone et al. Human alveolar macrophages: potentiation of their tumoricidal activity by liposome-encapsulated muramyl dipeptide.
Koff et al. Protection of mice against fatal herpes simplex type 2 infection by liposomes containing muramyl tripeptide
Fogler et al. Distribution and fate of free and liposome-encapsulated [3H] nor-muramyl dipeptide and [3H] muramyl tripeptide phosphatidylethanolamine in mice.
Fidler et al. The role of plasma membrane receptors and the kinetics of macrophage activation by lymphokines encapsulated in liposomes
Fidler et al. Activation of tumoricidal properties in peripheral blood monocytes of patients with colorectal carcinoma
Fidler et al. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide.